ZIMMER BIOMET HOLDINGS, INC. 10-Q

Item 2. Unregistered Sales of Equi ty Securities and Use of Proceeds Unregistered Sales of Equity Securities During the three-month period ended March 31, 2024, we issued 0.2 million shares of our common stock valued at $23.4 million upon the achievement of a commercial milestone related to the Embody acquisition. The shares were issued to the former Embody shareholders whom we reasonably believed to be accredited investors in a private transaction exempt from registration under Section 4(a)(2) and Regulation D under the Securities Act. To minimize dilution from issuing shares for the milestone settlement, we repurchased 0.2 million shares of our common stock in February 2024. Issuer Purchases of Equity Securities The following table summarizes repurchases of common stock settled during the three-month period ended March 31, 2024: Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as a Part of Publicly Announced Program (1) Maximum Approximate Dollar Value of Shares that may yet be Purchased Under the Program (1) January 2024 530,017 $ 120.94 530,017 $ 91,702,916 February 2024 192,737 123.87 192,737 67,828,222 March 2024 - - - 67,828,222 Total 722,754 $ 121.72 722,754 $ 67,828,222 (1) In February 2016, our Board of Directors authorized a $1.0 billion share repurchase program effective March 1, 2016, with no expiration date. Item 3. Defaults Upo n Senior Securities None Item 4. Mine Saf ety Disclosures Not applicable